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Abstract
Background:  Stroke thrombolysis-related intracerebral hemorrhage may occur remotely from
the anatomical  site  of ischemia. One  postulated  mechanism for  this  is  simultaneous multiple
embolization with hemorrhage into a "silent" area of ischemia.
Results:  A patient suffered a disabling stroke affecting the right cerebral hemisphere. He was
treated with intravenous alteplase and underwent extensive early imaging with multimodal MRI.
Several hours after treatment he developed a brainstem hemorrhage despite having no evidence of
ischemia on DWI MRI in the brainstem.
Conclusion:  Not all occurrences of remote ICH after stroke thrombolysis are secondary to
multiple emboli with silent ischemia.
Case
A 66-year-old right-handed man awoke from sleep feel-
ing well. At 06:55, while having breakfast, he developed
sudden onset of painless weakness of his left arm associ-
ated with left facial droop and a subtle change in sensa-
tion over the left face and arm. He went directly to his
local Emergency room where a diagnosis of stroke was
made. He was transferred immediately to our centre for
consideration of thrombolytic therapy, arriving at 08:28
(1 h 33 min from onset). He had a past history of a minor
stroke with full recovery 3 years previously and long-
standing hypertension. He was taking no medication
having elected to discontinue his anti-hypertensive ther-
apy two years earlier.
On examination, he was alert with no hemi-neglect or
aphasia. He had a left facial droop and slight dysarthria.
He was proximally weak but able to hold his left arm up
against gravity, but had completely absent left distal
hand function. He had reduced left leg power but was
able to walk unsteadily. There was a reduction in pin-
prick sensation over the left arm and face. He was in nor-
mal sinus rhythm with a blood pressure of 200/115. A
brain CT scan was performed, which demonstrated a
small old right anterior parietal infarct which was inter-
preted as consistent with his previous minor stroke.
There were no other acute changes. His National Insti-
tutes of Health Stroke Scale Score was 3.
Based on his clinical syndrome of severe distal weakness,
it was postulated that his stroke involved the primary
motor cortex or underlying fibres. After careful discus-
sion with the patient including explanation of the risks of
intracerebral hemorrhage, he was offered intravenous
alteplase therapy. His deficits were considered disabling
because of his retirement hobby of carpentry. His blood
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pressure fell to 170/95 with 10 mg of intravenous labe-
tolol, after which an intravenous alteplase infusion was
started at 09:28, 2 h 33 min after stroke onset. His blood
pressure remained controlled (<185/110) throughout the
infusion and subsequently with no change in his neuro-
logical status.
Immediately post-infusion (3 h 30 min from onset) he
underwent an acute brain magnetic resonance scan (Fig-
ure 1), which demonstrated a new stroke in the right pri-
mary motor cortex with a parallel perfusion deficit (not
shown). There was no perfusion-diffusion mismatch. No
additional lesions were observed in the brain (Figure 2).
All proximal intracranial arteries were patent on MR an-
giography.
Approximately 3 hours post-alteplase infusion (5 h 30
min from onset), he developed sudden vomiting and hy-
pertension followed by bradycardia. His level of con-
sciousness declined, he developed vertical strabismus
and he became hemiplegic on the left. He was intubated
and an urgent CT scan was performed (Figure 3) which
demonstrated a pontomesencephalic hemorrhage. He
died several weeks later from bronchopneumonia. An
autopsy was not performed. 
Discussion
Although most thrombolysis related intracerebral hem-
orrhages (ICH) occur at the site of stroke, up to 20% oc-
cur at sites away from the area of ischemia [1]. Despite
this, no brainstem hemorrhages occurred in the NINDS
tPA Stroke Trial and only 3% of ICH in the GUSTO-1 trial
were in the brainstem [2]. One postulated explanation
for the phenomenon of hemorrhage distant from the site
of ischemia has been that strokes from proximal embolic
sources, may be multiple such that co-existing small si-
lent strokes are the source areas of hemorrhage. Multiple
areas of DWI abnormality have been detected in a signif-
icant minority of patients with acute stroke [3].
This case concisely demonstrates that other mechanisms
are at play. By both clinical examination and early diffu-
sion-weighted imaging, there was no evidence of any
area of concomitant brainstem ischemia. It remains pos-
sible that he had an initial DWI abnormality in the pons
that was reversible with alteplase treatment, or that a
small DWI lesion was missed for technical reasons such
as slice thickness. DWI lesions associated with a brief du-
Figure 1
Post-alteplase infusion (~ 230 min after stroke onset) diffu-
sion weighted brain magnetic resonance image showing corti-
cal infarct in the motor strip
Figure 2
Post-alteplase infusion (~ 230 min after stroke onset) diffu-
sion  weighted  brain  magnetic  resonance  image  showing
absence of any acute lesion in the brainstem.BMC Neurology (2001) 1:1 http://www.biomedcentral.com/content/backmatter/1471-2377-
ration of ischemia have been clinically shown to be re-
versible [4]. We consider this possibility to be remote
because of his lack of clinical signs suggesting brainstem
ischemia. In addition, DWI lesions in both anterior and
posterior circulation concurrently are very uncommon
[5]. Finally, no perfusion deficit (mean transit time or
cerebral blood volume) was demonstrable in the pons.
Hypertensive small vessel disease was likely this pa-
tient's major risk factor for ICH. In phase 2 studies of al-
teplase for ischemic stroke, hypertension (diastolic BP >
100 mmHg immediately pre-treatment) was a clear risk
factor for ICH [6]. Although treating patients "off-proto-
col" has been shown in post-marketing studies to be as-
sociated with higher hemorrhage rates and poorer
outcomes [7], the NINDS protocol included both the
treatment of hypertension prior to administration of
thrombolytic therapy and the treatment of patients with
low NIHSS scores, but with disabling deficits. Recent ex-
perimental evidence suggests that chronically hyperten-
sive rats have higher rates of intracerebral hemorrhage
after alteplase therapy for stroke [8]. Nevertheless, the
NINDS investigators suggested that the treatment of hy-
pertension (after randomisation) in the alteplase treated
group was associated with poorer outcome but could not
draw definitive conclusions because of the trial's design
[9].
Conclusion
Thrombolysis-related ICH may occur unexpectedly and
even DWI MRI may not be predictive. The decision to
treat acute stroke patients with alteplase in the setting of
hypertension is still one based on clinical judgement
rather than solid evidence.
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Figure 3
6 h CT scan showing new pontomesencephalic hemorrhage.